Overview

A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers

Status:
Unknown status

Trial end date:
2017-12-01

Target enrollment:

Participant gender:

Summary

Diabetes mellitus is a common disease with much impact on human's health and is related to osteoporosis. But the mechanism remains unclear. The foreign researches revealed thiazolidinedione (TZD) would increase the risk of osteoporosis and bone fracture, specially elderly women. However, it is still controversial in terms of the youth and men. In Taiwan,there is few related study to analyze the relationship between TZD and steoporosis. This is a multicenter randomized controlled study.

Phase:

Phase 4

Details

Lead Sponsor:

National Taiwan University Hospital

Treatments:

Linagliptin
Pioglitazone